文档介绍：Commissioning Support
Exenatide (once-weekly)
(Bydureon®▼)
For the treatment of type 2 diabetes
Committee’s Verdict: CATEGORY B (Q3)
Commissioning considerations
NICE has advised that exenatide (10 µg twice daily) should be used as second- or third-line therapy after
metformin or a sulphonylurea in obese patients, or in patients in whom insulin therapy would have significant
occupational implications or weight loss would benefit other significant co-morbidities. The other GLP-1 agonist,
liraglutide, has been mended by NICE at a dose of mg daily but not at the higher dose of mg.
The efficacy of exenatide has not pared with liraglutide mg.
At current prices, the costs of one year’s treatment of exenatide 10 µg twice daily (plus needles), exenatide 2
mg once weekly, and liraglutide mg daily parable. Commissioners may want to consider use of
exenatide on the basis of cost as liraglutide is considerably more expensive (and not approved by NICE).
NICE guidance on the once-weekly formulation of exenatide is expected in February 2012.
Prescribing guidance
Exenatide (once weekly) should be initiated by a clinician with a special interest in diabetes, and can then be
prescribed in primary care according to NICE guidance on exenatide.
Category B: suitable for restricted prescribing under defined conditions
Q rati